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Recent studies revealed that elk-like S170N/N174T mutation in mouse prion protein (moPrP), which
results in an increased rigidity of b2-a2 loop, leads to a prion disease in transgenic mice. Here we
characterized the effect of this mutation on biophysical properties of moPrP. Despite similar ther-
modynamic stabilities of wild type and mutant proteins, the latter was found to have markedly
higher propensity to form amyloid ﬁbrils. Importantly, this effect was observed even under fully
denaturing conditions, indicating that the increased conversion propensity of the mutant protein
is not due to loop rigidity but rather results from greater amyloidogenic potential of the amino acid
sequence within the loop region of S170N/N174T moPrP.
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 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction barriers for disease transmission between different species. WhilePrion diseases or transmissible spongiform encephalopathies
(TSEs) are a group of fatal neurodegenerative disorders including
Creutzfeldt–Jakob disease and Gerstmann–Straussler–Scheinker
disease in humans, bovine spongiform encephalopathy in cattle,
scrapie in sheep and goat, and chronic wasting disease in cervids
[1,2]. The critical molecular event in TSE pathogenesis appears to
be the conformational conversion of the normal form of the prion
protein, PrPC, to a misfolded aggregated form, PrPSc. It is generally
believed that PrPSc itself represents the infectious prion agent,
which self-propagates by binding to PrPC and inducing conforma-
tional conversion of the latter protein to the PrPSc state. This ‘pro-
tein-only’ model is supported by wealth of experimental data [1,2],
most notably the recent success in generating infectious prions
in vitro from bacterially expressed recombinant PrP [3–6].
Despite the recent progress in prion research, the molecular
mechanisms of PrP conformational conversion and prion propaga-
tion remain poorly understood. This is largely due to challenges in
elucidating the structure of the infectious PrPSc conformer. Another
major challenge in the ﬁeld is to understand the molecular basis ofit appears that prion transmissibility is related to a complex inter-
play between the structure of donor PrPSc and conformational pref-
erences of host PrPC [7,8], molecular-level details of this interplay
are not clear.
High-resolution structures for the native form of PrP frommany
species have been determined by NMR and X-ray crystallography
[9,10]. The native protein consists of two distinct regions: a largely
disordered and ﬂexible N-terminal domain and a folded C-terminal
domain, each comprising approximately 100 amino acids [11]. The
folded domain contains three a-helices, two short b-strands, and
loops connecting these secondary structure elements [9,10,12,13].
Intriguingly, native PrPs from different species appear to have very
similar overall three-dimensional structures. The only region show-
ing substantial species-speciﬁc differences is the loop (residues
165–175 in huPrP) connecting the second strand of b-sheet to a-he-
lix 2. This b2-a2 loop is rigid in elk and bank vole, where a part of it
forms a 310-helix [14,15]. By contrast, in most other mammalian
species, the b2-a2 loop is disordered and ﬂexible [13,16,17]. Struc-
tural rigidity of b2-a2 loop appears to arise from the presence of
Asn at position 170, as indicated by the observation that, in contrast
to wild-type mouse prion protein (wt moPrP), NMR structures of
moPrP with elk PrP-mimicking S170N/N174T or vole PrP-mimick-
ing S170N amino acid substitutions are both characterized by a ri-
gid b2-a2 loop [14,15]. This loop has recently gained particular
interest following the observation that transgenic mice expressing
S170N/N174T moPrP spontaneously developed TSE disease,
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in the pathogenesis of prion diseases [18]. To gain insight into the
molecular basis of the latter ﬁnding, here we undertook biophysical
studies aimed at understanding the role of residues within the loop
region in PrP conformational conversion in vitro.
2. Materials and methods
2.1. Protein puriﬁcation
Full length wild type (wt) moPrP and the S170N/N174T variant
were expressed in Escherichia coli and puriﬁed as previously de-
scribed [19]. The proteins were stored in 10 mM sodium acetate
buffer (pH 4) at 80 C.
2.2. Thioﬂavin T (ThT) assay
The progress of amyloid ﬁbril formation was followed by a ﬂuo-
rimetric ThT assay [20]. The reaction under partially denaturing
conditions was performed by adding the protein (0.5 mg/ml) to
50 mM sodium phosphate buffer (pH 6.5) containing 2 M guani-
dine hydrochloride (GuHCl) (Thermo Scientiﬁc) and 40 lM ThT.
200 ll aliquots of this mixture were transferred to individual wells
of a 96-well plate (Micro-assay plate, Greiner Bio-one) containing a
3 mm glass bead (Fisher Scientiﬁc). The experiment was carried
out at 37 C using the Biotek FLx800 plate reader in a moderate
shaking mode. The excitation and emission wavelengths were
450 and 480 nm respectively. The reaction under fully denaturing
conditions was performed in a manual format as the reaction un-
der these conditions using the automated plate reader format
was very slowmaking suchmeasurements impractical. The protein
(0.5 mg/ml) was incubated in the same buffer as above but con-
taining 4 M GuHCl (but no ThT) at 37 C in 1.5 conical tubes (ﬁlled
to the volume of 1 ml) with continuous rotation at 8 rpm (Barn-
stead Thermolyne Labquake rotator). Five ll aliquots were with-
drawn at different time points and transferred to a quartz cell
containing 495 ll of 10 lM ThT in 50 mM sodium phosphate (pH
6.5). Fluorescence at 482 nm was measured in Fluoromax-3 (Hori-
ba Scientiﬁc) spectroﬂuorometer using the excitation wavelength
of 450 nm. In each case, ThT ﬂuorescence curves were ﬁt to the
equation [21]:
Y ¼ yi þ
yf
1þ eðtt0Þ=s ð1Þ
where yi and yf are the initial and ﬁnal baselines and t0 is the mid-
point of ﬁbrillization. Rate constant and lag phase are given by 1/s
and t0-2s respectively.
2.3. Equilibrium unfolding in GuHCl
The unfolding curves were obtained at 25 C using an automatic
titrator (Microlab 500 series) attached to an AVIV 215 circular
dichroism spectrometer. In these experiments, native proteins
(2 lM) in 50 mM phosphate buffer (pH 6.5) were titrated (in
0.07 M increments) with 8 M buffered GuHCl stock solution con-
taining identical protein concentration. Upon each addition of
GuHCl, the mixture was incubated for 30 s and the extent of pro-
tein unfolding was monitored by ellipticity at 222 nm. Unfolding
curves were analyzed according to the two-state folding model
[22].
2.4. Atomic force microscopy (AFM)
Sample were deposited on freshly cleaved mica, incubated for
1 min and then washed with pure water followed by drying with
nitrogen. All images were recorded in a tapping mode using aDigital Instruments Multimode atomic force microscope equipped
with Nanoscope IV controller. Data were processed and heights of
ﬁbrils were measured using Nanoscope SPM software package.
2.5. Electron microscopy
Fibrils were deposited on Formvar/carbon-coated grids and
negatively stained by incubating with 2% uranyl acetate solution
for 30 s. Electron micrographs were obtained using a JEOL
1200EX transmission electron microscope.
2.6. H/D exchange mass spectrometry (HXMS)
The HXMS experiments were performed essentially as de-
scribed previously [23–25]. Brieﬂy, amyloid ﬁbrils were incubated
in D2O for 24 h at 25 C. Fibrils were then dissociated into mono-
mers by treatment with ice-cold solution of 7 M GuHCl in 0.1 M
phosphate buffer (pH 2.4). These monomers were then diluted 10
times with ice cold 0.05% triﬂuoracetic acid in water and subjected
to pepsin digestion. The resulting peptic fragments were separated
on a C18 column and analyzed on-line for deuterium incorporation
by Finnigan LTQ mass spectrometer. The extent of deuterium
incorporation was calculated as:
%D ¼ ½mðtÞ mð0%Þ=½mð100%Þ mð0%Þ  100 ð2Þ
where %D is the relative amount of amide deuterium atoms incor-
porated in each peptic fragment, m(t) is the observed centroid mass
of the peptide at time point t, m(0%) is the measured mass of an
undeuterated reference sample, m(100%) is the observed mass of
a fully deuterated reference sample.
3. Results and discussion
While many factors may affect the pathogenesis of prion dis-
eases in vivo, the ﬁnding that rigid loop-inducing amino acid sub-
stitutions in moPrP are sufﬁcient to result in a spontaneous
development of TSE in transgenic mice [18] suggests that these
amino acid substitutions may increase the intrinsic ability of the
PrP to undergo conformational conversion to misfolded aggregated
form(s). To test this possibility, we compared the kinetics of amy-
loid ﬁbril formation in vitro by the recombinant protein corre-
sponding to wt moPrP and the rigid loop S170N/N174T variant.
Fibrillar aggregates formed by the recombinant PrP have been pre-
viously shown to cause TSE disease in animals [4,26]. However, the
infectivity of these preparations is usually much lower compared
to brain-derived prions, indicating that the structure of ﬁbrillar
aggregates formed in vitro is likely not fully equivalent to that of
brain PrPSc. Nevertheless, PrP amyloid ﬁbrils have been frequently
used as a convenient model in vitro to study mechanistic aspects of
PrP conformational conversion [27]. They are especially informa-
tive when used to assess the effect of species- or disease-speciﬁc
mutations on the conversion propensity of monomeric PrP to mis-
folded aggregates [28–30].
As in previous studies [28,29,31], ﬁbrillization experiments
were performed under partially denaturing conditions (2 M
GuHCl) that facilitate spontaneous ﬁbrillization of PrP in vitro.
The reaction was followed by the ThT ﬂuorescence assay in an
automated 96-well plate format. Consistent with previous studies
[32], wt moPrP forms amyloid ﬁbrils through a process character-
ized by a distinct lag period (corresponding to nuclei formation),
followed by a relatively rapid growth phase. As shown in Fig. 1,
the same characteristics are observed for the mutant protein. How-
ever, the reaction for the latter protein is much faster as compared
to wt moPrP, with the lag phases of 15.4 ± 1.0 h and 4.8 ± 0.47 h for
wt moPrP and S170N/N174T moPrP, respectively (Fig. 1). Thus,
elk-like PrP mutation that results in increased loop rigidity greatly
Fig. 2. GuHCl-induced equilibrium unfolding for wild type moPrP and the S170N/
N174T variant as monitored by ellipticity at 222 nm. The curves represent the
average of three experiments.
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experimental conditions. It should be noted that the ﬁnal ThT ﬂuo-
rescence intensity was substantially stronger for wt PrP ﬁbrils than
for the mutant PrP ﬁbrils (kinetic traces in Fig. 1 are intensity nor-
malized). While this could potentially suggest some degree of dif-
ferences in structural organization of ﬁbrils formed by the two
proteins, to the best of our knowledge, no correlation has yet been
established between ThT ﬂuorescence intensity and speciﬁc struc-
tural features of amyloid ﬁbrils.
It has been shown that the familial mutations within the folded
domain of humanPrP often result in thermodynamic destabilization
of the protein, and this reduced thermodynamic stability leads to an
increased propensity of PrP to undergo a conversion to amyloid ﬁ-
brils and other oligomeric b-sheet forms in vitro [28,29]. Therefore,
we testedwhether similar thermodynamic arguments couldbeused
to explain the observed increase in ﬁbrillization rate of the rigid loop
moPrP variants as compared to the wt protein. To this end, thermo-
dynamic stability of the proteinswas probed by equilibriumunfold-
ing inGuHCl using ellipticity at 222 nmas ameasure of the degree of
protein unfolding. Fig. 2 shows the unfolding curves for thewtmoP-
rP and the S170N/N174T variant. Surprisingly, these curves ap-
peared identical, indicating very similar thermodynamic
properties of the two proteins. This was conﬁrmed by the ﬁtting
analysis according to a two-state unfolding model [22], as both the
midpoint unfolding GuHCl concentrations (Cm) and free energy dif-
ferences between the native and unfolded state (DGu) were essen-
tially identical for wt moPrP (Cm = 2.33 ± 0.02 M, DGu = 5.0 ±
0.06 kcal/mol) and S170N/N174T moPrP (Cm = 2.33 ± 0.03 M,
DGu = 4.86 ± 0.09 kcal/mol). Therefore, greater ﬁbrillization pro-
pensity of the rigid loop variant is not due to the effect of amino acid
substitutions on the thermodynamic stability of the PrP.
Next, we asked the question whether the rigid loop-promoting
amino acid substitutions affect the ﬁnal structure of PrP amyloid
ﬁbrils. Formation of different types of ﬁbrils could potentially ex-
plain differences in ﬁbrillization kinetics of wt and mutant pro-
teins. However, when examined by atomic force microscopy,
ﬁbrils formed from wt moPrP and the S170N/N174T variant ap-
peared morphologically very similar. In both cases, ﬁbrils were of
variable length, and AFM images indicated the presence of both
individual protoﬁlaments as well as thicker (higher) structuresFig. 1. Time-course of amyloid ﬁbril formation for wild type moPrP and S170N/
N174T moPrP under partially denaturing conditions. Experiments were performed
in the presence of 2 M GuHCl. Each curve represents an average of at least three
independent experiments, with six replicates in each experiment. Error bars
represent standard error. For clarity of the ﬁgure, curves for wt and mutant proteins
were normalized to the same ThT ﬂuorescence intensity, even though the ThT
response for wt moPrP was approximately three times stronger compared to that
for the mutant protein.resulting from lateral association of these protoﬁlaments (Fig. 3A
and B). Height measurements in the regions corresponding to indi-
vidual protoﬁlaments revealed no difference between structures
formed by wt and mutant protein (4.3 ± 0.1 and 4.3 ± 0.2 nm for
wt and mutant PrP, respectively). Fibrils were further examined
by electron microscopy (Fig. 3C-F). Again, no measurable differ-
ences were found between the structures formed by the two pro-
teins. In both cases, most ﬁbrils appeared to consist of at least
two protoﬁlaments that self-associate into irregularly twisted
structures similar to those observed in previous studies with wt
mouse PrP [31]. Thus, despite differences in ThT ﬂuorescence
intensity (see above), no morphological differences could be de-
tected between the two ﬁbril types, at least within the resolution
limits of current AFM and EM measurements.
To compare the structural properties of ﬁbrils formed by the
two proteins at the molecular level, we employed the method of
hydrogen/deuterium exchange coupled with mass spectrometry.
By measuring the extent of deuterium labeling for individual pep-
tic fragments derived from ﬁbrillized proteins, this method allows
the identiﬁcation of systematically H-bonded b-sheet core region
of ﬁbrillar aggregates [23–25]. Previous studies mapped this amy-
loid core region in ﬁbrils formed by the recombinant human and
Syrian hamster PrP to residues 169–221 and 163–222, respec-
tively [23–25]. The b-sheet core region for ﬁbrils formed by moPrP
appears to be generally similar, as peptic fragments showing pro-
tection from deuterium labeling are limited to the 160–223 re-
gion (Fig. 4). Importantly, no signiﬁcant difference could be
detected between the ‘protection maps’ for ﬁbrils formed from
wt moPrP and the S170N/N174T variant, indicating essentially
identical core regions for both ﬁbril types (Fig. 4).
Very similar core regions for amyloids formed by wt moPrP and
the rigid loop variant do not rule out the possibility of subtle pack-
ing differences within these core regions (that could potentially ac-
count for differences in ThT ﬂuorescence intensity). Indeed,
differences in sheet-to-sheet interfaces have been previously
shown in crystal structures of six-residue peptide fragments corre-
sponding to the loop region (residues 170–175) in human/mo and
elk PrP [33–35]. These crystal structures show that the peptide de-
rived from elk PrP sequence forms a stronger and more prototypi-
cal steric zipper than that formed by the corresponding sequence
in human/mo PrP. However, high-resolution crystallographic stud-
ies are limited to short peptide fragments only, and it is not known
whether the packing of these peptides in crystals faithfully repre-
sents the structural properties of corresponding sequences in amy-
loid ﬁbrils formed by the full-length PrP.
Fig. 3. Morphology of ﬁbrillar structures formed by wt moPrP (left panels) and the
S170N/N174T variant (right panels). (A and B) Atomic force microscopy images in
height mode. The horizontal bar corresponds to 200 nm, and the vertical color bar
at the right side of each image represents height scale. Examples of individual (non-
associated) protoﬁlaments are marked with arrows. (C–F) Electron micrographs of
the two ﬁbril types. Scale bars in panels C and D correspond to 200 nm and those in
panels E and F correspond to 50 nm. Fibrils were prepared in 2 M GuHCl.
Fig. 4. Deuterium incorporation for peptic fragments derived from amyloid ﬁbrils
formed by wild type moPrP and S170N/N174T moPrP. Fibrils formed in 2 M GuHCl
were incubated for 24 h in D2O.
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tutions on the global thermodynamic stability of PrP and appar-
ently similar structural organization of ﬁbrillar aggregates
formed by wt and mutant PrP are intriguing, raising questions
regarding the mechanism by which these mutations could increasethe propensity of PrP for conformational conversion to misfolded
aggregates such as amyloid ﬁbrils. When considering this question,
one should note that PrP ﬁbrillization in vitro requires at least par-
tial destabilization/unfolding of the native protein structure. This is
typically accomplished by studying the reaction in the presence of
chemical denaturants such as urea or GuHCl [28,30,32]. The exper-
iments shown in Fig. 1 were performed in a buffer containing 2 M
GuHCl. Under these conditions, the monomeric PrP exists as a mix-
ture of different conformers including a natively folded protein, a
fully unfolded protein and, likely, a partially structured folding
intermediate [36]. Therefore, it is not clear whether the increased
amyloidogenic propensity of the S170N/N174T moPrP variant in
2 M GuHCl is indeed due to the presence of rigid loop in the native
PrP structure or rather it simply reﬂects an increased amyloido-
genic potential of the amino acid sequence containing these amino
acid substitutions, regardless of the speciﬁc PrP secondary struc-
ture. To probe this question, we repeated the ﬁbrillization experi-
ments in the presence of 4 M GuHCl (Fig. 5), i.e., under the
conditions in which PrP is fully unfolded, with no natively folded
protein present (see the unfolding curves in Fig. 2). Since these
measurements were impractical in the plate reader format (refer
to Section 2), they were performed in a manual format. Under
these conditions, the reactions for wt moPrP and the S170N/
N174T variant were characterized by lag phases of 22.5 ± 2.5 h
and 13.8 ± 2.0 h, respectively. Thus, it appears that also under fully
denaturing conditions, the S170N/N174T moPrP variant has higher
ﬁbrillization propensity than the wt protein.
Since side chain of Asn170 (present in rigid loop elk PrP and
S170N/N174T moPrP) has well deﬁned orientation and protrudes
from PrPC, whereas Ser170 (present in wt moPrP) is disordered
[14,37], it was previously suggested that the increased conversion
propensity of S170N/N174T moPrP to PrPSc as observed in animal
studies may be due to the ability of Asn170 to engage in long-range
intermolecular bonds with complementary sequences, as such
interactions could facilitate formation of steric zippers [18]. How-
ever, the present observation that S170N/N174T moPrP is more
amyloidogenic also under the denaturing conditions (i.e., when na-
tive rigid loop is no longer present) strongly suggests that this in-
creased amyloidogenicity is not necessarily due to loop rigidity per
se (or PrP secondary structure) but rather results from greater
intrinsic amyloidogenic potential of the amino acid sequence with-
in the loop region of S170N/N174T moPrP. This ﬁnding in vitro is
likely of physiological relevance as available data suggest that
the direct monomeric precursor of PrPSc is not the natively folded
Fig. 5. Time-course of amyloid ﬁbril formation for wild type moPrP and S170N/
N174T moPrP under fully denaturing conditions. Experiments were performed in
the presence of 4 M GuHCl. Solid lines show best ﬁts to Eq. (1). The lag phases are
22.5 ± 2.5 h and 13.8 ± 2.0 h for wild type moPrP and S170N/N174T moPrP
respectively. The lag phases were determined by ﬁtting individual ThT response
curves to Eq. (1), and these individual values from 3–4 experiments were used to
calculate the mean value and associated standard errors.
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structured folding intermediate [39,40]. Indeed, our present obser-
vations and conclusions are consistent with recent data on the role
of the b2-a2 loop in interspecies prion transmission in experimen-
tal animals [41]. The latter studies indicate that it is the identity in
the primary structure of the loop, particularly at position 170, and
not loop rigidity as such that inﬂuences cross-species seeding of
PrP conversion to PrPSc in vivo.
4. Conclusions
In summary, we have characterized biophysical properties of
prion disease-causing S170N/N174T variant of moPrP, ﬁnding that
this variant has substantially higher intrinsic amyloidogenic po-
tential as compared to wt moPrP. Despite the differences in ﬁbril-
lization kinetics, amyloid ﬁbrils formed by the wt and mutant
proteins appear to be structurally similar, at least at the level of
overall morphology and the identity of amyloid core region. It
was previously shown that, in contrast to wt moPrP, the native
structure of S170N/N174T moPrP is characterized by rigid b2-a2
loop. However, our present results argue that the increased conver-
sion propensity of the S170N/N174T variant is not necessarily due
to loop rigidity per se (or PrP secondary structure) but it reﬂects
greater amyloidogenic potential of the stretch of amino acids with-
in the 165–175 region of S170N/N174T moPrP.
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